'김갑성' 기자의 전체기사
-
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Br…
SUZHOU, China, Oct. 20, 2025 -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the indication of monotherapy for the treatment of HER2-positive advanced colorectal cancer (CRC) in patients who have failed prior treatments with oxaliplatin, fluorouracil and irino
- 김갑성 기자
- 2025-10-20 13:21
-
Alphamab Oncology Presented Multiple Clinical Data on Bipa…
SUZHOU, China, Oct. 20, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colorectal cancer (mCRC), along with the confirmatory study design of the phase III study of JSKN003 versus physician's choice of chemotherapy in platinum-resistant ovarian cancer (PROC) were presented as posters at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) from October 17 to 21, 2025,
- 김갑성 기자
- 2025-10-20 13:15
-
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituz…
CHENGDU, China, Oct. 20, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Z
- 김갑성 기자
- 2025-10-20 10:36
-
Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025…
SHANGHAI and HONG KONG, Oct. 20, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.&nbs
- 김갑성 기자
- 2025-10-20 09:00
-
CARsgen Presents Preliminary Results on Satri-cel for Adjuvan…
SHANGHAI, Oct. 20, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled "Adjuvant Therap
- 김갑성 기자
- 2025-10-20 08:15
-
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Onc…
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight. - The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration. - Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depo
- 김갑성 기자
- 2025-10-20 08:10
-
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF…
SUZHOU, China, Oct. 20, 2025 -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress. Key Highlights of CS2009 Poster Presentation:
- 김갑성 기자
- 2025-10-20 08:10
-
Clover Appoints Nicholas Jackson, Ph.D., as President of Glo…
SHANGHAI, Oct. 20, 2025 -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances. Dr. Jackson will work closely with the Company's CEO, Joshua Liang, to accelerate the development of Clover's RSV+hMPV±PIV3 combination vaccine candidates and lead potential alliances with global collaborators. "We are excited to welcom
- 김갑성 기자
- 2025-10-20 07:00
-
Significant OS Benefit with Cadonilimab in First-Line Advanced…
HONG KONG, Oct. 19, 2025 -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with oxaliplatin and capecitabine as first-line treatment for unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Professor Shen Lin, principal investigator from Peking University
- 김갑성 기자
- 2025-10-19 23:42
-
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneou…
[ 메디채널 김갑성 기자 ] Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therapy. Significant benefits were consistently observed with ivonescimab plus chemotherapy versus tislelizumab combination irrespective of PD-L1 expression. Ivonescimab combination therapy showed significant benefit over tislelizumab regimen in patients with or without liver metastase
- 김갑성 기자
- 2025-10-19 23:37
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-12_FRI
- ADSFF Mobilises Capital, Policy and Innovation to Drive the Next Era of Sustainability 02:42
- His Excellency affirmed that NDF has achieved significant international development milestones over the past fifty years, including more than USD 40 billion in assistance 01:35
- ZOWIE Elevates Esports Performance at Budapest Major 2025 01:00
- TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally 00:21
- ACE Shutters Notorious Piracy Operations in India 00:01
- Suvoda IRT named a Leader in Everest Group's RTSM PEAK Matrix® 00:00
- Gravity Launches Hybrid Casual Game 'Ragnarok Monster Kitchen' Worldwide! 00:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 12일 04시 20분